Merck and Moderna successfully test skin cancer vaccine
For the first time, an mRNA vaccine against cancer has reached its goals in a study relevant to approval. The data also caused euphoria on the stock exchange.
We haven't written up this one. Der Standard Wirtschaft has the full story — the link below goes straight to it.